Incyte Corporation and Moffitt Cancer Centre have entered a three-year research and collaboration agreement to jointly develop novel therapeutics approaches for hematologic malignancies.
According to the agreement, Incyte will fund the three new Moffitt Cancer Centre research programmes, which will be focused on developing specific therapeutic hypotheses involving Incyte’s proprietary small molecule therapeutics both as a single agent and in combination.
Sandoz AG, a manufacturer and marketer of pharmaceutical products, has acquired North American product portfolio of Euro-Pharm International, a pharmaceutical company, to strengthen and diversify its generic and consumer products in Canada.
The acquisition enables Sandoz AG to market Euro Pharm’s products in Canada, while Euro Pharm will continue to manufacture the products for Sandoz and will retain rights to commercialise the products outside North America.
Mylan N.V. plans to raise funds by issuing 3.95% of senior notes due in 2026 at 99.231% of the principal amount.
The company intends to use the gross proceeds of $2.25bn to acquire Meda and to repay, prepay or refinance its debts.
Pfizer plans to raise gross proceeds of $1.25bn through the public offering of 1.2% notes due in 2018, which is expected to be completed on 3 June 2016.
The company intends to invest the funds for general corporate purposes and also for repaying a part of its outstanding commercial paper.
Ixaltis, a pharmaceutical company, plans to develop its research of urinary incontinence through the funds raised in a financing round.
The financing was led by Irdinov fund, IXO Private Equity, Principia SAS, Sofimac Partners and Pierre Olivier Goineau, President of France biotech.
The company has raised gross proceeds of $8.9m through the financing round.
Image: Pfizer plans to raise gross proceeds of $1.25bn. Photo: Courtesy of Neruru.